Another Major Drug Approval for Regeneron
Congratulations to BCW member Regeneron on the approval of an important new drug to help patients with rheumatoid arthritis. The U.S. Food and Drug Administration has approved the human antibody drug sarilumab, developed by Regeneron Pharmaceuticals Inc. in Westchester and its French pharmaceutical partner Sanofi and trademarked as Kevzara, to treat adult patients with moderately to severely active rheumatoid arthritis.
The FDA approval came less than two months after the federal agency approved Regeneron’s and Sanofi’s human antibody dupilumab, marketed as Dupixent, as the first biologic medicine used to treat the debilitating itching and widespread rashes afflicting adults with moderate to severe cases of atopic dermatitis.
Similar News Items
Broadview at Purchase College, a university-based retirement community on the campus of the State University of New York in Westchester, held its official Grand Opening Thursday bringing together a host of dignitaries to celebrate a unique concept that champions intergenerational connections and lifelong learning. More than 400 people attended the festivities throughout the day, beginning […]
The BCW has announced it is continuing its partnership with Pace University’s Lubin School of Business and the Business Council of New York State in conducting a fourth business poll. This poll will focus on key issues that organizations are facing throughout New York City, Long Island, and Westchester County. These surveys seek to better […]
The Business Council of Westchester’s (BCW) Westchester Innovation Network is helping the video feedback platform Jotto introduce its technology to residents of the Yonkers Housing Authority. Developed by Quadrant 2, Jotto is a pioneering platform that leverages groundbreaking social justice applications to redefine community engagement for local government and large organizations. Jotto, a BCW WIN […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.